公开(公告)号：EP2417270A4

公开(公告)日：2012-09-12

申请号：EP10762298

申请日：2010-04-06

申请人： UNIV JOHNS HOPKINS ,  UNIV CASE WESTERN RESERVE

发明人： VOGELSTEIN BERT ,  KINZLER KENNETH W ,  LI MENG ,  DIAZ LUIS ,  PAPADOPOULOS NICKOLAS ,  MARKOWITZ SANFORD

IPC分类号： C12Q1/68 ,  C12N15/11 ,  G01N33/52

CPC分类号： C12Q1/6816 ,  C12Q1/6886 ,  C12Q2600/154 ,  C12Q2565/501 ,  C12Q2527/125 ,  C12Q2523/125

公开(公告)号：EP3218004A4

公开(公告)日：2018-06-13

申请号：EP15858277

申请日：2015-11-12

申请人： UNIV JOHNS HOPKINS

发明人： DIAZ LUIS ,  VOGELSTEIN BERT ,  KINZLER KENNETH W ,  PAPADOPOULOS NICKOLAS ,  LE DUNG

IPC分类号： A61K39/395 ,  A61P35/00

CPC分类号： C07K16/2803 ,  A61K2039/505 ,  A61K2039/55 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/30 ,  C07K16/40 ,  C07K2317/00 ,  C07K2317/24 ,  C07K2317/76 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Y113/11052

摘要： Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.

公开(公告)号：EP2697397A4

公开(公告)日：2014-10-15

申请号：EP12772013

申请日：2012-04-12

申请人： UNIV JOHNS HOPKINS

发明人： VOGELSTEIN BERT ,  KINZLER KENNETH W ,  PAPADOPOULOS NICKOLAS ,  KINDE ISAAC

IPC分类号： C12Q1/68 ,  C12N15/11

CPC分类号： C12Q1/6874 ,  C12Q1/6806 ,  C12Q1/6869 ,  C12Q1/6876 ,  C12Q2563/179 ,  C12Q2600/158 ,  C12Q2535/122 ,  C12Q2565/514

公开(公告)号：EP2326734A4

公开(公告)日：2012-07-11

申请号：EP09812193

申请日：2009-09-03

申请人： UNIV JOHNS HOPKINS

发明人： VOGELSTEIN BERT ,  KINZLER KENNETH W ,  PARSONS DONALD WILLIAM ,  JONES SIAN ,  ZHANG XIAOSONG ,  LIN JIMMY CHANG-HO ,  LEARY REBECCA J ,  ANGENENDT PHILIPP ,  PAPADOPOULOS NICKOLAS ,  VELCULESCU VICTOR ,  PARMIGIANI GIOVANNI ,  KARCHIN RACHEL ,  KERN SCOTT ,  HRUBAN RALPH ,  ESHLEMAN JAMES R ,  GOGGINS MICHAEL ,  KLEIN ALISON

IPC分类号： C12Q1/68

CPC分类号： G01N33/57438 ,  C12Q1/6886 ,  C12Q2600/156 ,  G01N2800/50

公开(公告)号：EP2315849A4

公开(公告)日：2012-02-22

申请号：EP09803662

申请日：2009-07-31

申请人： UNIV JOHNS HOPKINS

发明人： DIEHL FRANK ,  DIAZ LUIS ,  KINZLER KENNETH W ,  VOGELSTEIN BERT ,  SCHMIDT KERSTIN

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2525/197 ,  C12Q2535/131 ,  C12Q2549/119 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136

公开(公告)号：EP0672181A4

公开(公告)日：1997-03-26

申请号：EP93909210

申请日：1993-03-31

申请人： UNIV JOHNS HOPKINS MED

发明人： VOGELSTEIN BERT ,  KINZLER KENNETH W

IPC分类号： C12N15/09 ,  C07H21/04 ,  C12Q1/34 ,  C12Q1/68 ,  G01N33/50 ,  C12P19/34

CPC分类号： G01N33/50 ,  C12Q1/6806 ,  C12Q1/6886 ,  C12Q2600/156 ,  Y10S435/81 ,  Y10T436/143333 ,  C12Q2527/137

摘要： A method to isolate nucleic acids from stool specimen which is used to detect mutations associated with gastrointestinal neoplasia. An exemplary result obtained is shown in the Figure. Reagents used to carry out the isolation of nucleic acids are also disclosed.

公开(公告)号：EP3094313A4

公开(公告)日：2017-07-12

申请号：EP15737117

申请日：2015-01-14

申请人： UNIV JOHNS HOPKINS

发明人： VOGELSTEIN BERT ,  ZHOU SHIBIN ,  KINZLER KENNETH W ,  SUR SUROJIT

IPC分类号： A61K9/127 ,  A61K31/166 ,  A61K31/525 ,  A61K47/40

CPC分类号： A61K31/525 ,  A61K9/1271 ,  A61K9/1278 ,  A61K31/166 ,  A61K47/40 ,  A61K47/6951

摘要： The invention provides liposome compositions comprising liposomes encapsulating cyclodextrins that both bear ionizable functional groups, such as on their solvent-exposed surfaces, and encompass therapeutic agents, as well as uses thereof.

摘要翻译： 本发明提供包含包封环糊精的脂质体组合物，所述脂质体既包含可离子化的官能团，例如在其溶剂暴露的表面上，又包含治疗剂，以及其用途。

公开(公告)号：EP2726869A4

公开(公告)日：2015-03-11

申请号：EP12804757

申请日：2012-06-28

申请人： UNIV DUKE ,  UNIV JOHNS HOPKINS

发明人： YAN HAI ,  BIGNER DARELL ,  VOGELSTEIN BERT ,  KINZLER KENNETH W ,  MEEKER ALAN ,  HRUBAN RALPH ,  PAPADAPOULOS NICKOLAS ,  DIAZ LUIS ,  JIAO YUCHEN

IPC分类号： G01N33/53 ,  A61K31/7105 ,  A61K39/00 ,  C12Q1/68

CPC分类号： C12Q1/6886 ,  C07K16/40 ,  C12N15/1137 ,  C12Q2600/118 ,  C12Q2600/156 ,  G01N33/57407

摘要： We determined the sequence of ATRX and DAXX in 447 cancers from various sites. We found mutations most commonly in pediatric glioblastoma multiformae (GBM) (11.1%), adult GBM (6.5%), oligodendrogliomas (7.7%) and medulloblastomas (1.5%); and showed that Alternative Lengthening of Telomeres (ALT), a telomerase-independent telomere maintenance mechanism found in cancers that have not activated telomerase, perfectly correlated with somatic mutations of either gene. In contrast, neuroblastomas, and adenocarcinomas of the ovary, breast, and pancreas were negative for mutations in ATRX and DAXX. Alterations in ATRX or DAXX define a specific molecular pathway that is closely associated with an alternative telomere maintenance function in human cancers.

公开(公告)号：EP2729582A4

公开(公告)日：2015-02-25

申请号：EP12807137

申请日：2012-07-06

申请人： UNIV JOHNS HOPKINS

发明人： VOGELSTEIN BERT ,  KINZLER KENNETH W

IPC分类号： C12Q1/68 ,  C12N15/11

CPC分类号： C12Q1/6827 ,  C12Q1/6883 ,  C12Q1/6886 ,  C12Q2527/107 ,  C12Q2561/125

公开(公告)号：EP2723896A4

公开(公告)日：2015-02-18

申请号：EP12802288

申请日：2012-06-22

申请人： UNIV JOHNS HOPKINS

发明人： VOGELSTEIN BERT ,  KINZLER KENNETH W ,  WU JIAN ,  DIAZ LUIS ,  PAPADOPOULOS NICKOLAS ,  MATTHAEI HANNO ,  HRUBAN RALPH ,  MAITRA ANIRBAN

IPC分类号： C12Q1/68 ,  C12N15/11

CPC分类号： C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/156

摘要： To help reveal the pathogenesis of these lesions, we purified the DNA from Intraductal Papillary Mucinous Neoplasm (IPMN) cyst fluids from 19 patients and searched for mutations in 169 genes commonly altered in human cancers. We identified recurrent mutations at codon 201 of GNAS. We found that GNAS mutations were present in 66% of IPMNs and that either KRAS or GNAS mutations could be identified in 96%. In eight cases, we could investigate invasive adenocarcinomas that developed in association with IPMNs containing GNAS mutations. In seven of these eight cases, the GNAS mutations present in the IPMNs were also found in the invasive lesion. GNAS mutations were not found in other types of cystic neoplasms of the pancreas or in invasive adenocarcinomas not associated with IPMNs. These data suggest that GNAS mutations can inform the diagnosis and management of patients with cystic pancreatic lesions.